March 1, 2024 07:05 AM ESTUpdated 09:47 AM
People
R&D

Grit­stone bio lays off 40% of staff fol­low­ing Covid vac­cine tri­al de­lay

Katherine Lewin

News Reporter

Vac­cine biotech Grit­stone bio is cut­ting its head­count by about 40% af­ter it an­nounced ear­li­er this month that the Phase IIb …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

Benev­o­len­tAI CEO is out af­ter less than a year on the job

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times